Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.
$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | Mkt Perform | Raymond James | |
| 10/4/2024 | $10.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/30/2024 | $16.00 → $10.00 | Buy → Hold | TD Cowen |
| 7/25/2024 | $18.00 → $12.00 | Overweight → Neutral | JP Morgan |
| 5/29/2024 | $15.00 | Neutral | Robert W. Baird |
| 5/29/2024 | $8.00 | Sell | Citigroup |
| 4/17/2024 | $24.00 → $14.00 | Neutral → Underperform | BofA Securities |
| 12/12/2023 | $21.00 | Hold | Deutsche Bank |
8-K - Sage Therapeutics, Inc. (0001597553) (Filer)
10-Q - Sage Therapeutics, Inc. (0001597553) (Filer)
8-K - Sage Therapeutics, Inc. (0001597553) (Filer)
Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S. Topline data from the DIMENSION Study in Huntington's Disease (HD) expected late 2024 Cash, cash equivalents and marketable securities of $569 million as of September 30, 2024 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. "We are committed to harnessing the full potential of ZURZUVAE as
Planned workforce reduction of approximately 33% of employees expected to extend the company's cash runway Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced a strategic reorganization of its business operations to support the ongoing launch of ZURZUVAE in postpartum depression and focus pipeline development efforts ahead of a clinical study readout for dalzanemdor in Huntington's Disease expected later this year. The reorganization is intended to enable Sage to strengthen its balance sheet, extend cash runway, and position the company for long-term growth potential. The reorganization is planned to be substantially completed by the end of the 4th quarter of 2024 and expected to: Im
Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments ind
Raymond James resumed coverage of SAGE Therapeutics with a rating of Mkt Perform
RBC Capital Mkts downgraded SAGE Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $10.00 previously
TD Cowen downgraded SAGE Therapeutics from Buy to Hold and set a new price target of $10.00 from $16.00 previously
JP Morgan analyst Anupam Rama downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Neutral and lowers the price target from $18 to $12.
Baird analyst Joel Beatty maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $15 to $13.
HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $25 price target.
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)
Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S. Topline data from the DIMENSION Study in Huntington's Disease (HD) expected late 2024 Cash, cash equivalents and marketable securities of $569 million as of September 30, 2024 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. "We are committed to harnessing the full potential of ZURZUVAE as
Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments ind
Achieved $7.4 million in ZURZUVAE™ (zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter More than 1,400 prescriptions shipped and delivered during the second quarter of 2024, nearly doubling from the first quarter Dalzanemdor (SAGE-718) topline data from the LIGHTWAVE (Alzheimer's Disease) and DIMENSION (Huntington's Disease) Studies expected in late 2024; primary endpoint for DIMENSION Study adjusted from HD-CAB composite to the Symbol Digit Modalities Test (SDMT) SAGE-324 did not meet the primary endpoint in participants with essential tremor (ET); Sage and Biogen terminated
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005117/en/Jessica Federer (Photo: Business Wire) "We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Jessica's innate curiosit
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage's current and emerging product pipeline through all stages of development. "We are thrilled to have Dr. Gault join Sage to lead the development and delivery of our pipeline of potential new medicines and be a partner in our mission to improve the lives of people affected by brain health disorders," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Dr. Gault's vision, experience and deep commitment to this field of med
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi as Chief Commercial Officer. In his new role, Mr. Benecchi will lead Sage's global commercial efforts across all Sage programs, new product planning, strategy, and competitive intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005386/en/Chris Benecchi, Chief Commercial Officer, Sage Therapeutics (Photo: Business Wire) "Chris Benecchi is an innovator, a transformative global
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
3 - Sage Therapeutics, Inc. (0001597553) (Issuer)
4 - Sage Therapeutics, Inc. (0001597553) (Issuer)
For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas
For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health